Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Novartis/Schering AG Re-Evaluating PTK/ZK Development Due To Low Probability Of Survival Benefit

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firms plan to reconsider NDA submission strategy after interim analysis of CONFIRM-2 trial suggests PTK/ZK 787 is unlikely to yield survival benefit in second-line metastatic colorectal cancer.

You may also be interested in...



Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.

Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.

Novartis/Schering AG's Vatalanib Efficacy Not CONFIRMed; Filing Delayed Until 2007

Colorectal cancer agent fails to meet primary endpoint of central radiology review-assessed progression-free survival in the CONFIRM-1 trial, Novartis says. The company expects data on overall survival for the agent, also known as PTK-ZK, to be available in the second half of 2006.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS062646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By